Device Center Strategic Priorities: Equity, Resilience, Staff Development
Executive Summary
The US FDA’s device center has set strategic priorities for 2022-2025 of promoting a modern and diverse workforce, enhancing organizational agility and resilience, and advancing health equity. A new report lays out how the agency plans to pursue these goals.
You may also be interested in...
FDA's US-First Strategy: Device Center Sets Three-Year Goals
A new three-year plan to implement strategic priorities at US FDA's device center aims to make several broad improvements to the medtech ecosystem. Among them is improving staff incentives at the agency, creating more partnerships with industry and other stakeholders, and improving the center's processes to make it easier for novel medical devices to enter the US market.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.